1. Home
  2. CORT

as of 11-20-2026 3:59pm EST

$63.63
$1.20
-1.85%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Founded: 1998 Country:
United States
United States
Employees: N/A City: REDWOOD CITY
Market Cap: 7.6B IPO Year: 2001
Target Price: $142.60 AVG Volume (30 days): 1.2M
Analyst Decision: Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: annual
EPS: 1.13 EPS Growth: -33.33
52 Week Low/High: $28.66 - $126.38 Next Earning Date: 11-03-2026
Revenue: $761,407,000 Revenue Growth: 12.79%
Revenue Growth (this year): 52.09% Revenue Growth (next year): 44.73%
P/E Ratio: 57.37 Index: N/A
Free Cash Flow: 141.8M FCF Growth: +19.16%

Stock Insider Trading Activity of Corcept Therapeutics Incorporated (CORT)

Sell
CORT Nov 10, 2026

Avg Cost/Share

$74.07

Shares

1,500

Total Value

$111,105.00

Owned After

0

SEC Form 4

Sell
CORT Nov 3, 2026

Avg Cost/Share

$82.35

Shares

13,159

Total Value

$1,082,277.19

Owned After

14,480

Sell
CORT Nov 2, 2026

Avg Cost/Share

$81.42

Shares

11,841

Total Value

$964,074.09

Owned After

14,480

SEC Form 4

Vieira Roberto Wandenkolk

President, Oncology

Sell
CORT Nov 2, 2026

Avg Cost/Share

$81.13

Shares

8,333

Total Value

$674,068.80

Owned After

5,622

Sell
CORT Oct 15, 2026

Avg Cost/Share

$115.39

Shares

10,000

Total Value

$1,148,082.74

Owned After

1,054,843

SEC Form 4

Form 1 Form 2
Sell
CORT Oct 2, 2026

Avg Cost/Share

$116.12

Shares

9,190

Total Value

$1,067,257.94

Owned After

10,427

Maduck Sean

See Remarks

Sell
CORT Oct 2, 2026

Avg Cost/Share

$116.34

Shares

24,587

Total Value

$2,858,884.37

Owned After

14,480

Vieira Roberto Wandenkolk

President, Oncology

Sell
CORT Oct 2, 2026

Avg Cost/Share

$115.61

Shares

8,333

Total Value

$967,447.91

Owned After

5,622

SEC Form 4

Form 1 Form 2
Sell
CORT Oct 1, 2026

Avg Cost/Share

$115.40

Shares

810

Total Value

$93,472.79

Owned After

10,427

SEC Form 4

Maduck Sean

See Remarks

Sell
CORT Oct 1, 2026

Avg Cost/Share

$115.54

Shares

413

Total Value

$47,716.90

Owned After

14,480

SEC Form 4

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 3, 2026 · 100% conf.

AI Prediction SELL

1D

-5.71%

$78.08

Act: -3.31%

5D

-7.43%

$76.66

20D

-7.12%

$76.91

Price: $82.81 Prob +5D: 0% AUC: 1.000
0001628280-26-069494

EX-99.1

2 cort110326ex991pressrelease.htm

EX-99.1

Document

EXHIBIT 99.1

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

•Revenue of $340.5 million, a 64 percent increase over the same period in 2025

◦Korlym® and authorized generic product revenue of $249.1 million

◦Lifyorli® product revenue of $91.4 million

•Reiterated 2026 revenue guidance of $1.1 – $1.2 billion

•Net income of $126.8 million, compared to $19.7 million in third quarter 2025

•Net income per common share (diluted) of $1.01, compared to $0.16 in third quarter 2025

•Quarterly cash and investments increase of $117.7 million, to $662.3 million

•BELLA Part A trial results in platinum-resistant ovarian cancer: Patients who received Lifyorli (relacorilant) in addition to nab-paclitaxel and bevacizumab demonstrated clinically meaningful progression-free survival (PFS), objective response rate (ORR) and overall survival (OS), with the most pronounced results being in patients earliest in their course of treatment in the platinum-resistant setting, including patients who had no prior treatment with bevacizumab

REDWOOD CITY, Calif., (November 3, 2026) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the third quarter.

Financial Results

“Awareness of the importance of diagnosing and treating patients with Cushing’s syndrome is steadily increasing and is driving the growth of our endocrinology business,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer. “Lifyorli’s uptake in ovarian cancer has been both very rapid and broad. Since its April 1st launch, more than 2,300 patients have received the medication. More than 1,700 physicians have prescribed it. We expect continued growth in both businesses and have reiterated our 2026 revenue guidance of $1.1 – $1.2 billion.”

Corcept’s third quarter 2026 revenue was $340.5 million, compared to $256.1 million in the second quarter of 2026. Korlym and authorized generic revenue increased 19 percent, to $249.1 million. Lifyorli revenue grew 92 percent, to $91.4 million.

Third quarter 2026 operating expenses were $225.7 million, compared to $214.8 million in the second quarter of 2026. Third quarter 2026 net income was $126.8 million, compared to $43.0 million in the second quarter of 2026.

Cash and investments were $662.3 million at September 30, 2026, compared to $544.6 million at June 30, 2026. The balance at September 30, 2026 reflects the acquisition of $43.7 million of common stock in the third quarter pursuant to the company’s stock repurchase program as well as shares acquired upon the exercise of employee stock options and the vesting of restricted stock grants.

Clinical Development

Hypercortisolism (Cushing’s Syndrome)

•American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD)’s Consensus Report on the Management of Type 2 Diabetes, published in October 2026, recommends screening for hypercortisolism in diabetic patients with poor glucose control despite ongoing medications; cites mifepristone as a potentially beneficial treatment

•Relacorilant for patients with Cushing’s syndrome – Resubmitted New Drug Application Prescription Drug User Fee Act (PDUFA) date of December 17, 2026

“The ADA and EASD consensus statement is an important advance for the many patients whose difficult-to-control hyperglycemia is a manifestation of undiagnosed Cushing’s syndrome,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. “Optimal care starts with screening and a correct diagnosis. The ADA/EASD report also identifies mifepristone as a potential treatment, citing the positive results of our CATALYST trial.”

Oncology

Relacorilant in Combination with Chemotherapy

•BELLA Part A –Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab in 95 patients with platinum-resistant ovarian cancer demonstrated clinically meaningful median PFS of 7.2 months, ORR of 59 percent and OS of 88 percent at 6-months (median OS not yet reached at the time of the primary analysis); benefit was most pronounced among patients who had not received bevacizumab previously (these patients had received fewer prior lines of treatment): median PFS of 8.1 months, ORR of 66 percent and 6-month OS of 91 percent; safety profile of relacorilant plus nab-paclitaxel and bevacizumab was consistent with the known profiles of each individual agent, with no new safety signals identified

•BELLA Part B – Enrollment nearing completion in Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab in 90 patients with platinum-sensitive ovarian cancer whose disease progressed while on a PARP inhibitor – Results expected by the end of next year

•BELLA Part C – Enrollment completed in Phas

2026
Q2

Q2 2026 Earnings

8-K BUY

Jul 29, 2026 · 100% conf.

AI Prediction BUY

1D

+5.74%

$98.28

Act: +27.29%

5D

+8.76%

$101.09

20D

+16.08%

$107.89

Price: $92.95 Prob +5D: 100% AUC: 1.000
0001628280-26-050607

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1785594423.309030a0

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2026
Q1

Q1 2026 Earnings

8-K BUY

Apr 30, 2026 · 100% conf.

AI Prediction BUY

1D

+5.02%

$48.86

Act: +10.73%

5D

+8.62%

$50.53

Act: +9.74%

20D

+11.34%

$51.80

Act: +49.22%

Price: $46.52 Prob +5D: 100% AUC: 1.000
0001628280-26-028892

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1784333127.cc7d85a9

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

Share on Social Networks: